[1]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281-282.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
　Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(04):281-282.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
点击复制

胰高血糖素样肽-1与骨骼肌葡萄糖代谢()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年04期
页码:
281-282
栏目:
小论坛
出版日期:
2014-08-31

文章信息/Info

Title:
Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle
作者:
黄婷婷; 沈飞霞; 谷雪梅
325000　温州医科大学附属第一医院内分泌科 　　
Author(s):
Huang Tingting; Shen Feixia; Gu Xuemei.
Department of Endocrinology，The First Affiliated Hospital of Wenzhou Medical University， Wenzhou 325000，china Corresponding author：Gu Xuemei，Email：snowgxm@126.com
关键词:
胰高血糖素样肽-1; 骨骼肌; 葡萄糖代谢
Keywords:
Glucagon-like peptide-1; Skeletal muscle; Glucose metabolism
DOI:
10.3760/cma.j.issn.1673-4157.2014.04.019
摘要:
胰高血糖素样肽-1（GLP-1）具有葡萄糖依赖的促胰岛素分泌及降糖作用。其促进胰岛素释放，抑制胰高血糖素产生，从而调节血糖。骨骼肌作为重要的维持糖代谢平衡的胰岛素靶器官，存在丰富的GLP-1受体。GLP-1通过作用于受体可增强葡萄糖转运及促进糖原合成。
Abstract:
Glucagon-like peptide-1（GLP-1） plays an important role in glucose-dependent insulinotropic and antidiabetic properties. GLP-1 stimulates insulin secretion and inhibits glucagon release，thereby regulating blood glucose. As an important insulin target organ，skeletal muscle with abundant GLP-1 receptors maintains a balance of glucose metabolism. GLP-1 enhances glucose transport and glycogen synthesis by binding GLP-1 receptor on skeletal muscular cells.

参考文献/References:

　[1]　Dailey MJ，Moran TH.Glucagon-like peptide 1 and appetite[J]. Trends Endocrinol Metab，2013，24（2）： 85-91. 　
[2]　Leech CA，Dzhura I，Chepurny OG，et al.Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells[J].Prog Biophys Mol Biol，2011，107（2）：236-247. 　
[3]　Hare KJ，Vilsb?覬ll T，Asmar M，et al.The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action[J].Diabetes，2010，59（7）：1765-1770. 　
[4]　Asmar M，Holst JJ.Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide：new advances[J].Curr Opin Endocrinol Diabetes Obes，2010，17（1）：57-62. 　
[5]　Bak AM，Egefjord L，Gejl M，et al.Targeting amyloid-beta by glucagon-like peptide -1（GLP-1） in Alzheimer's disease and diabetes[J].Expert Opin Ther Targets，2011，15（10）：1153-1162. 　
[6]　Green CJ，Henriksen TI，Pedersen BK，et al.Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia[J].PLoS One，2012，7（8）：e44284. 　
[7]　Fan R，Li X，Gu X，et al.Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage：potential involvement of AKT and mitochondria biogenesis[J].Diabetes Obes Metab，2010，12（9）：815-824. 　
[8]　Ayala JE，Bracy DP，James FD，et al.The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake Independent of its incretin action[J].Endocrinology，2009，150（3）：1155-1164. 　
[9]　Villanueva-Pen~acarrillo ML，Martín-Duce A，Ramos-álvarez I，et al.Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients[J].Regul Pept，2011，168（1-3）：39-44.
[1０]　Foley K，Boguslavsky S，Klip A.Endocytosis，recycling，and regulated exocytosis of glucose transporter 4[J].Biochemistry，2011，50（15）：3048-3061.
[11]　Chai W，Dong Z，Wang N，et al.Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism[J].Diabetes，2012，61（4）：888-896.
[12]　Chai W，Wang W，Liu J，et al.Angiotensin Ⅱ type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use[J].Hypertension，2010，55（2）：523-530.
[13]　Chai W，Wang W，Dong Z，et al.Angiotensin Ⅱ receptors modulate muscle microvascular and metabolic responses to insulin in vivo[J]. Diabetes，2011，60（11）：2939-2946.
[14]　Moreno P，Nuche-Berenguer B，Gutiérrez-Rojas I，et al.Normal-izing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states[J].J Mol Endocrinol，2012，48（1）：37-47.
[15]　Aas V，Hessvik NP，Wettergreen M，et al.Chronic hyperglycemia reduces substrate oxidation and impairs metabolic switching of human myotubes[J].Biochim Biophys Acta，2011，1812（1）：94-105.
[16]　Holst JJ，Vilsb?覬ll T，Deacon CF.The incretin system and its role in type 2 diabetes mellitus[J].Mol Cell Endocrinol，2009，297（1-2）：127-136.
[17]　Defronzo RA，Tripathy D.Skeletal muscle insulin resistance is the primary defect in type 2 diabetes[J].Diabetes Care，2009，32（Suppl 2）：S157-S163.
[18]　Arnés L，Moreno P，Nuche-Berenguer B，et al.Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle，in normal and type 2 diabetic state[J].Regul Pept，2009，153（1-3）：88-92.
[19]　Liu Z， Liu J，Jahn LA，et al.Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvascu-lature[J]. J Clin Endocrinol Metab，2009，94（9）：3543-3549.

相似文献/References:

[1]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
　Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(04):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[2]孙洁,杨兵全,孙子林.自噬与糖尿病骨骼肌病变[J].国际内分泌代谢杂志,2014,(03):194.[doi:10.3760/cma.j.issn.1673-4157.2014.03.014]
　Sun Jie*,Yang Bingquan,Sun Zilin..Autophagy in diabetic myopathy[J].International Journal of Endocrinology and Metabolism,2014,(04):194.[doi:10.3760/cma.j.issn.1673-4157.2014.03.014]
[3]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
　Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(04):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[4]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
　Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[5]吴海洋,黄祯子,彭嘉欣,等.胰高血糖素样肽-1与肾素-血管紧张素系统的交互作用[J].国际内分泌代谢杂志,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
　Wu Haiyang,Huang Zhen-zi,Peng Jiaxin,et al.Interaction between glucagon-like peptide-1 and renin angiotensin system[J].International Journal of Endocrinology and Metabolism,2016,36(04):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
[6]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
　Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(04):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[7]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
　Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(04):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[8]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
　Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[9]王永 乐岭.GLP-1对血管重构中血管平滑肌细胞的影响[J].国际内分泌代谢杂志,2018,38(01):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
　Wang Yong,Yue Ling.Effects of GLP-1 on vascular smooth muscle cells in vascular remodeling[J].International Journal of Endocrinology and Metabolism,2018,38(04):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
[10]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
　Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(04):645.[doi:10.3760/cma.j.cn121383-20200924-09046]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金资助项目（81000356） 通信作者：谷雪梅，Email:snowgxm@126.com
更新日期/Last Update: 2014-07-20